Orthoson Limited

Overview

Legal name

ORTHOSON LIMITED

Region

South East England

Registered address

THE MAGDALEN CENTRE

ROBERT ROBINSON AVENUE

OXFORD

UNITED KINGDOM

OX4 4GA

Insolvency history

No

Latest accounts

Financial period: 1 Jul 2024 to 30 Jun 2025

FULLACCOUNTS

Turnover

Unknown

Profit / Loss

Unknown

Employees

12

Company events

Reference milestones and recent Companies House filing stream events.

6 events

31 Mar

2027

Accounts due

Accounts Due

Next accounts due date

06 Oct

2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

22 Sep

2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun

2025

Accounts filed

Accounts

Last accounts made up date

09 Oct

2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQzODkwMTQyNGFkaXF6a2N4

Published 09 Oct 2024 09:28

28 Sep

2015

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards

First funded

2019

Funded years

2019, 2020, 2023

Age at first award

3 years

Projects

2023 Collaborative R&D Lead participant

System for Annulus Fibrosus Repair (SAFR) – a percutaneously implantable preformed biomaterial for the repair of defects caused by either degenerative disc disease or needle puncture during nucleus pulposus replacement procedures SAFR

1 Jun 2023 to 28 Feb 2025

Awarded

£1,129,165

Total cost £1,613,093

The SAFR seeks to address the existing market challenge for an annulus fibrosus repair device to prevent the extrusion of nucleus pulposus material that occurs during any minimally invasive discectomy treatment or surgical needle puncture to the Annulus Fibrosus. OrthoSon aims to bring to market an innovative, disruptively simple solution of UK origin tha...

2020 Feasibility Studies Lead participant

Restoring performance of the spine with a minimally invasive procedure, performed through a needle (Project Number 105080) - COVID-19 update

1 Jun 2020 to 30 Nov 2020

Awarded

£250,000

Total cost £250,000

no public description

2019 Feasibility Studies Lead participant

Restoring performance of the spine with a minimally invasive procedure, performed through a needle

1 Apr 2019 to 31 Mar 2021

Awarded

£1,202,078

Total cost £1,717,254

"Lower back pain is a worldwide health problem, affecting up to 85 % of people at some point in their life. It is often caused by degeneration, due to ageing of the intervertebral disc, which is located between two vertebrae and allows bending and twisting of the spine as well as resilience under compression. There is presently no method for repairing or ...

Product types

Collaborative R&D Feasibility Studies